Fig. 1: Elevated LFTs among patients with COVID-19.
a, Overview of cohort 1. n = 99 patients required hospitalization due to COVID-19 (Germany). n = 72 were admitted due to moderate/severe COVID-19 and n = 27 acquired COVID-19 during their hospital stay. b, Only 1.4% of patients admitted due to COVID-19 from cohort 1 had a history of liver disease, yet LFTs at admission showed elevated AST in 63% and ALT in 39% of patients. c,d, AST and ALT levels in patients with COVID-19 acquired during hospitalization worsened after COVID-19 diagnosis in 81% and 67% of patients, respectively. e, Demographic overview of cohort 2. n = 1,219 patients required hospitalization due to COVID-19 (Michigan). Only 2.4% of admitted patients from cohort 2 had a history of liver disease, yet LFTs at admission show elevated AST in 57% and ALT in 37% of patients with COVID-19. f, Variation of mean AST and ALT over time in patients with COVID-19, showing elevations in LFTs associated with mortality.
